Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease.

Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease.

Sphingolipids are important in many brain functions but their role in Alzheimer's disease (AD) is not completely defined. A major limit is availability of fresh brain tissue with defined AD pathology. The discovery that cerebrospinal fluid (CSF) contains abundant nanoparticles that include syna...

Full description

Bibliographic Details
Main Authors:	Alfred N Fonteh, Cora Ormseth, Jiarong Chiang, Matthew Cipolla, Xianghong Arakaki, Michael G Harrington
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4418746?pdf=render

Similar Items

Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease[S]
by: Alfred N. Fonteh, et al.
Published: (2013-10-01)

Polyunsaturated Fatty Acid Composition of Cerebrospinal Fluid Fractions Shows Their Contribution to Cognitive Resilience of a Pre-symptomatic Alzheimer’s Disease Cohort
by: Alfred N. Fonteh, et al.
Published: (2020-02-01)

Plasma Lipolysis and Changes in Plasma and Cerebrospinal Fluid Signaling Lipids Reveal Abnormal Lipid Metabolism in Chronic Migraine
by: Katherine Castor, et al.
Published: (2021-08-01)

ABCA1‐Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease
by: Hussein N. Yassine, et al.
Published: (2016-02-01)

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)

Compromised Behavior and Gamma Power During Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau
by: Roger Rochart, et al.
Published: (2020-10-01)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
by: Mychael V. Lourenco, et al.
Published: (2020-01-01)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
by: Umesh Gangishetti, et al.
Published: (2018-09-01)

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
by: Kenta Yoshida, et al.
Published: (2020-01-01)

High Correlation among Brain-Derived Major Protein Levels in Cerebrospinal Fluid: Implication for Amyloid-Beta and Tau Protein Changes in Alzheimer’s Disease
by: Kyoka Hoshi, et al.
Published: (2022-04-01)

Non-immunoglobin in cerebrospinal fluid of patients with Alzheimer's disease and cerebral amyloid angiopathy.
by: Esiri, M, et al.
Published: (1985)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
by: Sebastian Palmqvist, et al.
Published: (2019-12-01)

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.
by: Mikko Hölttä, et al.
Published: (2013-01-01)

Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.
by: Ebba Gløersen Müller, et al.
Published: (2019-01-01)

The Major Components of Cerebrospinal Fluid Dictate the Characteristics of Inhibitors against Amyloid-Beta Aggregation
by: Andrius Sakalauskas, et al.
Published: (2023-03-01)

Amyloid‐beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome
by: Ioanna Stylianaki, et al.
Published: (2020-07-01)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease.
by: Nina Schultz, et al.
Published: (2019-01-01)

A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.
by: Adrianna Z Herskovits, et al.
Published: (2013-01-01)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
by: Yuk Yee Leung, et al.
Published: (2015-09-01)

Alpha desynchronization during simple working memory unmasks pathological aging in cognitively healthy individuals.
by: Xianghong Arakaki, et al.
Published: (2019-01-01)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
by: Mahsa Dolatshahi, et al.
Published: (2018-07-01)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
by: Samar Rahhal, et al.
Published: (2023-12-01)

Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women
by: Fanni Haapalinna, et al.
Published: (2016-07-01)

C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease
by: María-Salud García-Ayllón, et al.
Published: (2017-05-01)

An LC-MS/MS-based platform for the quantification of multiple amyloid beta peptides in surrogate cerebrospinal fluid
by: Merve Oztug, et al.
Published: (2024-01-01)

Corrigendum to “Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency”
by: Samar Rahhal, et al.
Published: (2023-12-01)

Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta
by: Zeynep Tufekcioglu, et al.
Published: (2023-10-01)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
by: Said HM, et al.
Published: (2022-04-01)

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
by: Tapiola, T, et al.
Published: (2009)

Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
by: Anna M. De Kort, et al.
Published: (2021-09-01)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
by: Rosengren Lars, et al.
Published: (2009-12-01)

Amyloid beta and Alzheimer’s Disease: The role of neprilysin-2 in amyloid-beta clearance
by: Robert eMarr, et al.
Published: (2014-08-01)

Amyloid Beta in Aging and Alzheimer’s Disease
by: Ujala Sehar, et al.
Published: (2022-10-01)

BETA-AMYLOID AS PATHOGENESIS OF ALZHEIMER DISEASE
by: Kadek Ary Mahendri Pattni
Published: (2013-07-01)

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans
by: Sohee Moon, et al.
Published: (2021-01-01)

Early onset diagnosis in Alzheimer’s disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid
by: Jusung An, et al.
Published: (2024-02-01)

β-Amyloid (1–42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
by: Elmar Kaiser, et al.
Published: (2011-11-01)

Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau.
by: Aysha S Mohamed Lafirdeen, et al.
Published: (2019-01-01)

Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
by: Anna M. De Kort, et al.
Published: (2021-11-01)

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
by: Koen Delmotte, et al.
Published: (2021-04-01)